August 15, 2024 U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
July 18, 2024 European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT)
June 11, 2024 Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
Archive June 3, 2024 Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Archive April 29, 2024 Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion
Archive April 9, 2024 Deciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Archive February 6, 2024 Deciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial Results
Archive February 1, 2024 Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024
Archive February 1, 2024 Deciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
